PanOptica
develops and commercializes ocular therapies and eye drops for the treatment of ophthalmic diseases... Read morePanOptica
develops and commercializes ocular therapies and eye drops for the treatment of ophthalmic diseases... Read more
News
Jun 17, 2021
MarketScreener
PanOptica: PanOptica Announces Licensing Agreement with Zhaoke Ophthalmology for PAN-90806 for the Treatment of Neovascular Eye Diseases in China, South Korea, and Southeast Asia
Oct 10, 2019
MarketScreener
PanOptica: PanOptica Anti-VEGF Eye Drop Shows Promise in Treatment of Neovascular (Wet) AMD
Oct 07, 2019
BioPortfolio
PanOptica: PanOptica to Present Positive Topical AntiVEGF Eye Drop Data at OISAAO
Aug 13, 2018
BioPortfolio
PanOptica: PanOptica Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 10052018 Prices from USD $250
May 22, 2018
BioPortfolio
PanOptica: PanOptica Doses First Patient with New Formulation of PAN90806 a Novel Topical AntiVEGF Eye Drop in Phase 12 Clinical Trial
Oct 17, 2017
funding smes
PanOptica: PanOptica Raises $11 Million Series B
Oct 10, 2017
Global Corporate Venturing
PanOptica: PanOptica sees $11m in series B
Oct 09, 2017
PharmaLeaders
PanOptica: PanOptica secures $11m to advance clinical development novel topical anti-VEGF eye drop
Oct 07, 2017
Venture Capital Access Online
PanOptica: PanOptica Secures $11 Million to Advance Clinical Development of PAN-90806 � a Novel, Topical Anti-VEGF Eye Drop
Oct 06, 2017
FierceBiotechIT
PanOptica: SV, Third Rock back clinical-phase wet AMD biotech
